Biotech and pharma marketing can't run live creative tests the way consumer brands do. Every concept that goes into MLR review costs weeks if it's wrong. We pre-test messaging and concepts with HCPs and patients before submission, so what reaches medical legal regulatory review has already survived contact with the audience.
The Problem
Unvalidated Creative Burns MLR Review Cycles
Every concept submitted to MLR consumes a review slot, whether it survives or not. Ship three untested directions and lose two on claims language or tone, and you don't just lose the concepts. You lose the weeks legal and medical spent flagging them, then restart from scratch. That review-cycle time is the real cost, not the creative fee.
No Live A/B Testing Means No Real-World Signal Before Launch
DTC brands ship a variant, watch the data, and kill what doesn't convert within days. You can't. Regulated claims mean you can't run live creative splits against HCPs or patients without a compliance review first. If nobody runs a rigorous qualitative test before that, you're launching on the strategist's gut instinct instead of evidence.
Concept Panels and MLR Reviewers Never Talk to Each Other
Marketing runs a message board with physicians. Separately, medical and legal review claims language against label requirements. These processes rarely share findings before submission, so a concept that tests well with HCPs on comprehension can still get flagged in MLR for a claims-support gap the panel never asked about.
Agencies Scope Iteration Too Wide, Not Too Narrow
The instinct is to bring MLR a menu: five headlines, three visual directions, two tones. It feels thorough. It's the opposite, because MLR now adjudicates five times the claims exposure, and every extra concept is another chance for a rejection that resets the clock. Tight scoping before submission is what keeps timelines predictable.
How We Help
We start by auditing what's happening between your creative process and your MLR queue. We pull the last two or three review cycles and map where concepts got killed, at what stage, and whether the rejection reason was something a pre-test would have caught. Most teams have never done this mapping. They know MLR is slow. They rarely know their rejections trace back to the same recurring gaps in claims support or tone.
From that audit we build a pre-testing protocol scoped to your product: HCP message boards for claims and mechanism language, patient concept panels for tone and comprehension, sized to the therapeutic area. We decide up front what we're testing for, comprehension, credibility, claims tolerance, with your medical and regulatory leads in the room before creative work starts.
We narrow creative to two, sometimes three, directions before anything goes to a live panel. That's the discipline agencies skip. Fewer directions means a tighter test and fewer variants for MLR to adjudicate. We moderate the HCP and patient sessions ourselves or alongside your research vendor, then translate feedback into specific direction: what language holds up, what claim needs a data citation, what visual reads as overpromising to a physician.
Iteration happens here, before submission, not after a rejection. We hand the creative team a short, specific punch list, not a redo-everything memo, so the concept that reaches MLR has already been stress-tested against the questions review is going to ask.
Once a concept clears MLR and launches, we track it against the same comprehension and credibility measures used in pre-testing, and keep a running log of what gets flagged and why across campaigns, so your team stops repeating the same claims mistakes.
What we deliver
- MLR Rejection Audit – a review of your last several submission cycles mapping where concepts got killed and why.
- HCP and Patient Pre-Testing Protocol – a repeatable message-board and concept-panel framework built with your medical and regulatory leads.
- Narrowed Creative Direction Package – two to three pre-tested concepts with a specific punch list, replacing the wide-menu approach.
- Post-Launch Performance Tracking – comprehension and credibility tracking against the pre-test baseline, plus a running log of claims flags.
The cost of unvalidated creative in biotech and pharma isn't a bad ad, it's the weeks of MLR review time you spend finding out it was bad.
Our Methodology
We run this as a 90-day sprint because pharma marketing already operates on review cycles, and a sprint fits inside that rhythm. Day one to thirty is assessment and protocol: we map your MLR rejection history and get medical and regulatory sign-off on what we're testing for before creative starts.
Day thirty to sixty is where pre-testing happens: HCP message boards and patient concept panels against a narrowed set of directions, translated into a specific punch list. Day sixty to ninety is submission and measurement, tracking the pre-tested concept's performance against the baseline.
This isn't a one-time engagement. It's a system your team keeps running after we hand it off, because the value compounds every cycle you use it.
How We Work
Weeks one through four: we embed with marketing, medical, and regulatory to run the rejection audit and build the pre-testing protocol, with two to three working sessions a week.
Weeks five through eight: we run the pre-test itself and turn results into creative direction. This is the highest-touch phase, with a weekly session and a shared document tracking every finding against every concept.
Weeks nine through twelve: the narrowed concept goes into formal MLR submission, and we track post-launch performance against the pre-test baseline. Cadence drops to biweekly, and we hand off the protocol as a document your team owns going forward.
Typical engagement runs $15,000 to $40,000 per month, depending on concurrent launches and how much panel research we run directly versus coordinating with your existing vendor.
- Fewer MLR rejections tied to claims or tone issues a pre-test would have caught earlier.
- Shorter time from creative kickoff to approved, launch-ready asset.
- A pre-testing protocol your team keeps using on every future launch, not a one-off deliverable.
If your biotech & pharma company needs creative testing & iteration leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does biotech and pharma creative testing cost?
Most engagements run $15,000 to $40,000 per month, depending on how many concurrent launches you're testing and whether we run HCP and patient panels directly or coordinate with your existing vendor. Complex claims areas like oncology or rare disease sit at the higher end because the protocol needs more rounds. We scope pricing after the initial MLR rejection audit.
How long does the pre-testing process take?
The full sprint runs 90 days: 30 to audit your MLR history and build the protocol, 30 to run pre-testing and iterate creative, and 30 to submit and track post-launch performance. Individual pre-test rounds typically take one to two weeks including recruitment. Teams with well-documented MLR history can compress the assessment phase.
How do you work with our medical, legal, and regulatory teams?
We build the pre-testing protocol with your medical and regulatory leads from day one, not after creative is built. They tell us what MLR actually flags, and we design panel questions around that. Your MLR process stays exactly as it is; we add a testing layer in front of it.
How is this different from what our creative agency already does?
Most agencies test for likeability or recall, then hand a wide menu of concepts to MLR and let legal sort out which survive. We test for claims tolerance and comprehension, narrow to two or three directions before submission, and build the protocol around what your reviewers actually flag. The agency still makes the creative; we make sure it survives review.
How do you measure whether the pre-testing is working?
We track MLR outcomes, how many rounds a concept takes to clear and what gets flagged, and post-launch comprehension and credibility scores against the pre-test baseline. If rounds per concept drop and launched creative performs in line with what pre-testing predicted, the protocol is working. We log this across campaigns so the pattern is visible over multiple launches.
What kind of biotech or pharma company is the right fit for this?
Series A through growth-stage companies with at least one asset close to or past approval, where MLR has become a bottleneck or is being stood up for the first time. If you're pre-clinical with no commercial creative in flight, this isn't the right engagement yet. If you're already submitting multiple concepts a quarter and losing weeks to rejections, this is built for you.
